Targeted therapy medications may be used for the treatment of advanced or recurrent uterine cancer, especially in cases where the cancer cells have specific molecular targets that can be inhibited. Some targeted therapy medications used for uterine cancer treatment include:

• Pembrolizumab (Keytruda): Pembrolizumab is a monoclonal antibody that can help the immune system attack cancer cells. It may be used alone or in combination with chemotherapy for advanced or recurrent uterine cancer that has certain molecular features.
• Bevacizumab (Avastin): Bevacizumab is a monoclonal antibody that can help stop the growth of blood vessels that supply nutrients to cancer cells. It may be used in combination with chemotherapy for advanced or recurrent uterine cancer.
• Everolimus (Afinitor): Everolimus is a medication that can help stop cancer cells from dividing and growing by targeting specific cellular pathways. It may be used in combination with hormonal therapy for advanced or recurrent uterine cancer.
• Trastuzumab (Herceptin): Trastuzumab is a monoclonal antibody that can help stop the growth of cancer cells that overexpress the HER2 protein. It may be used in combination with chemotherapy for advanced or recurrent uterine cancer.

It is important to note that targeted therapy medications may have different side effects and risks compared to traditional chemotherapy, and may not be suitable for all patients. A healthcare provider can provide more information about the potential benefits and risks of targeted therapy for uterine cancer.

Hormone therapy medications may be used for the treatment of uterine cancer in cases where the cancer cells have specific hormone receptors that can be targeted. The two most common hormone therapy medications used for uterine cancer treatment are:

• Progestins: Progestins are synthetic versions of the hormone progesterone, which can help stop the growth of uterine cancer cells. Progestin therapy may be used for women with early-stage or recurrent uterine cancer who have hormone receptor-positive tumors.
• Aromatase inhibitors: Aromatase inhibitors can help reduce the amount of estrogen in the body by blocking the enzyme aromatase, which converts androgens into estrogens. Aromatase inhibitor therapy may be used for women with early-stage or recurrent uterine cancer who have hormone receptor-positive tumors.

It is important to note that hormone therapy medications may have different side effects and risks compared to traditional chemotherapy, and may not be suitable for all patients. A healthcare provider can provide more information about the potential benefits and risks of hormone therapy for uterine cancer.